Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015

April 30, 2015

GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Thursday, May 7, 2015.

In addition, management will host a conference call to discuss the quarterly results and provide an update on corporate activities.

Conference call details are as follows:

Date: May 7, 2015

Time: 4:30 pm US Eastern Time

Dial-in number: (877) 212-6076 (Domestic) or (707) 287–9331 (International)

Via web: www.novavax.com, "Investor Info"/"Events"

Conference call replay:

Dates: Starting at 7:30 pm ET on May 7, 2015 until midnight May 14, 2015

Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode: 35660022

Via web: www.novavax.com, "Investor Info"/"Events"

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-MTM adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, www.novavax.com.

```
CONTACT: Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
```

Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations

<u>ir@novavax.com</u> 240-268-2000

Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.

david.schull@russopartnersllc.comtodd.davenport@russopartnersllc.com 212-845-4271

Novavaxologor type unknown

Novavax, Inc.